LL-37 Research Overview (also known as Cathelicidin)
The only known human cathelicidin antimicrobial peptide, produced by immune cells and epithelial tissues as part of innate immune defense. Studied for broad-spectrum antimicrobial activity against bacteria, fungi, and viruses, as well as wound healing acceleration, immune modulation, and regulation of chronic inflammatory pathways.
What Is LL-37?
LL-37 is the only member of the cathelicidin family of antimicrobial peptides in humans — a 37-amino-acid peptide cleaved from its precursor protein hCAP18 by the enzyme kallikrein. It is an amphipathic helical peptide produced by neutrophils, macrophages, mast cells, and epithelial cells at sites of infection and inflammation, representing a front-line innate immune defense factor.
Antimicrobial and Antibiofilm Mechanism
LL-37 kills bacteria, fungi, viruses, and parasites through direct membrane disruption — inserting into microbial membranes and forming pores that lyse the cell. Its broad-spectrum activity covers gram-positive bacteria (including MRSA), gram-negative bacteria, enveloped viruses, and fungi. Crucially, it is active against biofilm — the organized, drug-resistant matrix that allows bacteria to evade conventional antibiotics — making it particularly relevant for chronic wound infection research.
Wound Healing and Immunomodulation
Beyond antimicrobial activity, LL-37 promotes keratinocyte migration and proliferation (re-epithelialization), stimulates angiogenesis via VEGF receptor transactivation, and modulates macrophage activity to promote the M2 healing phenotype. It also attracts neutrophils and monocytes, stimulates mast cell degranulation, and directly activates dendritic cells — shaping both innate and adaptive immune responses to infection.
Quick Reference
| Literature-Reported Dose Range | 0.5-1.6 mg/mL |
| Literature-Reported Frequency | Daily to twice weekly based on wound type |
| Literature-Reported Cycle Length | 2-8 weeks depending on wound healing progress |
| Literature-Reported Washout | Continue until complete healing achieved |
| Storage | Refrigerate 2-8°C, protect from light, use within expiration |
| Timing | Apply after wound cleaning, can be used with standard dressings |
Research Indications
Wound Healing
Chronic Venous Leg Ulcers
Clinical trials show 68% ulcer area reduction with 0.5 mg/mL concentration
Diabetic Foot Ulcers
Enhanced granulation tissue formation and healing rate in clinical studies
Pressure Ulcers
Chitosan hydrogel delivery systems demonstrate accelerated healing in animal models
Immunity
Local Antimicrobial Protection
Broad-spectrum activity against wound pathogens including antibiotic-resistant bacteria
Biofilm Disruption
Effective against established bacterial biofilms in chronic wounds
Infection Prevention
Reduces bacterial colonization and prevents wound infection progression
Skin Health
Epithelial Cell Proliferation
Stimulates keratinocyte migration and proliferation for faster wound closure
Angiogenesis Promotion
Enhances VEGF production and new blood vessel formation
Collagen Synthesis
Supports proper extracellular matrix formation and tissue strength
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Chronic Venous Ulcers | 0.5 mg/mL | Twice weekly | Topical gel application |
| Diabetic Foot Ulcers | 0.5-1.6 mg/mL | Daily application | Topical cream |
| Acute Wound Healing | 1.6 mg/mL | Once daily | Topical gel or cream |
| Pressure Ulcer Treatment | 0.5-1.0 mg/mL | Twice daily | Hydrogel delivery system |
| Burn Wound Care | 1.0 mg/mL | Once to twice daily | Topical gel application |
Timing
Apply after wound cleaning, can be used with standard dressings. Typical onset: initial response: 1-2 weeks; Significant healing: 4-6 weeks; Complete healing: varies by wound.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
Combined anti-inflammatory and healing effects with LL-37 providing antimicrobial activity and TB-500 enhancing cellular migration and angiogenesis.
LL-37 demonstrates synergistic effects with chloramphenicol, ciprofloxacin, and oxacillin against multidrug-resistant bacteria, with FICI values 0.25-0.5.
Vitamin D3 acts as cofactor for VDR to induce endogenous LL-37 production, enhancing innate immune responses and antimicrobial activity.
Both antimicrobial peptides can be used together safely with no documented negative interactions in wound healing applications.
High salt concentrations in physiological environments can reduce LL-37 antimicrobial activity. Consider dosing adjustments in high-salt conditions.
Physical incompatibility may occur with certain amino acid solutions, particularly in IV formulations. Avoid co-administration in same solution.
Limited data on interactions with other synthetic antimicrobial peptides. Clinical interaction profile not established for most combinations.
LL-37 activates TLR7 and TLR9 pattern recognition receptors, which are constitutively hyperactive in autoimmune conditions including SLE (lupus), rheumatoid arthritis, and Sjögren's syndrome. Use without physician supervision in these conditions risks triggering or worsening immune flares.
LL-37 activates FPRL1 (FPR2) which promotes pro-survival cell signaling. In vitro studies have shown LL-37 can support survival of some cancer cell lines. Anyone with active cancer or a recent cancer history should consult an oncologist before use.
Both are immune-modulating compounds. Stacking two immunomodulatory peptides can push immune activation in unpredictable directions, especially in individuals with pre-existing immune dysregulation. Monitor for signs of immune over-activation.
Reported Research Timeline
01Week 1–2 (reported in cited studies): reduced bacterial load, initial wound bed preparation
02Week 2–4 (reported in cited studies): increased granulation tissue formation, epithelial migration
03Week 4–6 (reported in cited studies): significant wound size reduction, improved healing quality
04Week 6–8 (reported in cited studies): continued healing progress toward complete wound closure
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Use only on clean, debrided wounds as directed by healthcare provider
Monitor for signs of wound infection or delayed healing
Discontinue if signs of hypersensitivity or allergic reactions develop
Use sterile technique for application to prevent contamination
Individuals with active autoimmune conditions (lupus/SLE, rheumatoid arthritis, Sjögren’s syndrome) should not use LL-37 without physician supervision. LL-37 activates TLR7 and TLR9 pattern recognition receptors, which are constitutively hyperactive in these conditions and can trigger or worsen immune flares.
Anyone with a history of cancer — particularly breast, ovarian, or colorectal — should consult an oncologist before use. LL-37 activates FPRL1 (FPR2), a receptor that promotes pro-survival signaling in some cancer cell lines in vitro.
Dose-dependent cytotoxicity: at concentrations above established research doses, LL-37 disrupts cell membranes non-selectively. Do not exceed published research dose ranges — more is not better and carries direct cellular toxicity risk.
Injection site reactions (redness, warmth, transient pain) are common and expected — the antimicrobial peptide activates local immune responses. Rotate injection sites and monitor for signs of actual infection vs. expected inflammatory response.
Seek Medical Attention If:
Signs of wound infection (increased redness, warmth, purulent drainage)
Allergic reactions or contact dermatitis around application site
Worsening wound condition or delayed healing progression
Development of unusual pain or irritation at application site
Quality Indicators
Verified Marker
Sterile formulation
Topical LL-37 should be sterile with preservatives appropriate for wound care
Verified Marker
Appropriate gel base
Compatible gel or cream base that doesn't interfere with peptide activity
Verified Marker
Proper concentration
Clinical-grade concentrations (0.5-1.6 mg/mL) with verified potency
Verified Marker
Cold storage maintenance
Maintained at 2-8°C throughout storage and transport
Quality Concern
Contaminated products
Any signs of microbial contamination or non-sterile preparation
Quality Concern
Improper pH formulation
pH outside physiological range that could irritate wound tissue
Acceptable Range
Homemade formulations
DIY topical preparations may lack sterility and proper formulation
Research Citations
- Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial
Grönberg, A., Mahlapuu, M., Ståhle, M., Whately-Smith, C., Rollman, O., 2014, Wound Repair and Regeneration - LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity
Keshri, A.K., Rawat, S.S., Chaudhary, A., Sharma, S., Kapoor, A., Mehra, P., Kaur, R., Mishra, A., Prasad, A., 2025, International Journal of Antimicrobial Agents - Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles
Wang, G., 2008, Journal of Biological Chemistry - Antimicrobial peptide LL-37 is bactericidal against Staphylococcus aureus biofilms
Noore, J., Noore, A., Li, B., 2019, PLOS ONE - The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Ridyard, K.E., Overhage, J., 2021, Antibiotics - Discovery of novel antibacterial agent for the infected wound treatment: all-hydrocarbon stapling optimization of LL-37
Zhang, Y., Zheng, M., Wang, Z., Liu, Z., Chen, S., Li, X., Shi, Y., Hu, H., 2024, Theranostics - LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases
Bhattacharjya, S., Zhang, Z., Ramamoorthy, A., 2024, Biomolecules - Alanine and lysine scans of the LL-37-derived peptide fragment KR-12 reveal key residues for antimicrobial activity
Gunasekera, S., Muhammad, T., Strömstedt, A.A., Rosengren, K.J., Göransson, U., 2018, ChemBioChem - Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy
Liu, R., Xu, Y., Chen, M., Weïwer, M., Zhou, X., Bridges, A.A., DeJesus, M.A., Kelley, L., Negami, T., Vo, N.N., et al., 2021, Pharmacological Research - LL-37-derived short antimicrobial peptide KR-12-a5 and its d-amino acid substituted analogs with cell selectivity, anti-biofilm activity, synergistic effect with conventional antibiotics, and anti-inflammatory activity
Kim, E.Y., Rajasekaran, G., Shin, S.Y., 2017, European Journal of Medicinal Chemistry - LL-37, a Multi-Faceted Amphipathic Peptide Involved in NETosis
Radic M, Muller S, 2022, Cells - Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease
Miao S, Liu H, Yang Q, 2024, Pharmacol Res - Human cathelicidin peptide LL-37 induces endothelial-to-mesenchymal transition
Suzuki K, Ohkuma M, Nagaoka I, 2025, Biosci Biotechnol Biochem - Human host-defense peptide LL-37 targets stealth siderophores
Zsila F, Beke-Somfai T, 2020, Biochem Biophys Res Commun - Human Cathelicidin Peptide LL-37 Induces Cell Death in Autophagy-Dysfunctional Endothelial Cells
Suzuki K, Ohkuma M, Someya A, 2022, J Immunol
"
Research Focus
Antimicrobial, Wound healing, Immune modulation, Biofilm disruption, Anti-inflammatory, Skin health
Verified Vendors Carrying LL-37
Frequently Asked Questions
What should researchers watch for with LL-37?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with LL-37?
Week 1–2 (reported in cited studies): reduced bacterial load, initial wound bed preparation
How is LL-37 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →